The ETFDH gene helps your cells turn fats and some proteins into usable energy, especially during fasting or exercise. If this gene does not work well, the body can struggle to meet energy needs and certain breakdown products can build up. Pathogenic variants in the ETFDH gene are linked to multiple acyl-CoA dehydrogenase deficiency, a condition that can cause low blood sugar, muscle weakness, vomiting, and liver or heart problems. Some forms begin later in life and may improve with riboflavin treatment.
What is a gene?
Genes are stretches of DNA that hold instructions your cells use to make molecules or regulate processes in the body. Some genes provide the directions for producing proteins, which are the functional parts of cells. Others mainly guide when certain processes happen, where they take place, and how active they are. Taken together, genes affect how your body develops and works, and they can influence how you respond to food, stress, and medications. For a deeper look at this topic, you can read more in the LearnHub.
Overview
ETFDHGene function
What if the gene works
The ETFDH gene helps mitochondria, your cells’ energy centers, turn fats and some protein building blocks into usable energy. Its protein passes electrons between steps in this process, helping muscles and other tissues meet everyday energy needs.
Risk
What if the gene does not work
Variants in the ETFDH gene can cause multiple acyl-CoA dehydrogenase deficiency, which limits energy production from fats and proteins. Milder variants may cause later muscle weakness and exercise intolerance, while more severe variants can cause early metabolic illness.
Treatment
What does that mean for your treatment
Pathogenic or loss-of-function variants in the ETFDH gene often make riboflavin (vitamin B2) a central treatment choice, because many people with ETFDH-related disease respond well to it. Care may also include carnitine when levels are low, along with avoiding fasting and diet changes to support energy use.
Conditions associated with ETFDH
Gene function
What if the gene works
Your muscles and other tissues need a steady way to turn food into usable energy. The ETFDH gene supports this process inside mitochondria, the parts of cells that act like energy centers. It helps move energy from fat and some protein breakdown into the cell’s main power-making system. This is part of how the ETFDH gene helps make energy from fat in the body.
Inside mitochondria, the ETFDH gene helps pass electrons (tiny energy packets) from food breakdown into the cell’s power-making chain. This lets cells capture energy in a controlled way.
Many tissues rely on fat for fuel between meals or during longer activity. Through its protein, the ETFDH gene connects fat breakdown to the steps that make usable cell energy.
Some amino acids, the building blocks of protein, can also be used for energy. This gene helps route that released energy into the same mitochondrial system.
By linking several fuel processing enzymes to the main energy system, the ETFDH gene supports steady ATP production. ATP is the cell’s main energy currency, used for movement and other routine work.
What is a variant?
A genetic variant is a minor difference in the DNA sequence within a gene. These differences are common and help shape normal human diversity, including variation in appearance, metabolism, and the way the body responds to environmental influences. Many variants do not have any noticeable effect and are simply part of natural genetic variation. In some situations, though, a variant can change how a gene functions more significantly and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the ETFDH gene can make the protein unstable, misshapen, or less able to pass electrons inside mitochondria, the cell's energy centers. This shows how ETFDH gene variants affect protein function, from milder changes that leave some activity to more severe variants that greatly reduce or stop it. In ETFDH related multiple acyl-CoA dehydrogenase deficiency, that functional range can influence whether symptoms start in infancy or later and how strongly they show up.
How variants are linked to conditions
Pathogenic variants in the ETFDH gene cause multiple acyl-CoA dehydrogenase deficiency, also called glutaric acidemia type II. In ETFDH gene related conditions, the presentation can range from severe early illness in newborns to later-onset muscle weakness, exercise intolerance, and episodes of low blood sugar. Some people with ETFDH-related disease have a riboflavin-responsive form, which is a well-established pattern seen in clinical practice.
A variant is not necessarily a diagnosis
Genetic variants are a routine part of human biology and are common throughout the general population. Most do not have a direct effect on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition indicates a possible link rather than a definite diagnosis, especially when multiple genes and environmental factors also play a role. In some situations, however, a single well-characterized variant in a specific gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For ETFDH, risk is mainly set by the gene change itself, especially when a child inherits nonworking copies from both parents. In people living with ETFDH-related illness, fasting, infections, and heavy exercise can trigger or worsen symptoms. Some medicines may also make symptoms more likely, so medication review is important.
Inheritance of ETFDH variants
ETFDH inheritance for well-established ETFDH-related conditions follows an autosomal recessive pattern. This means a person usually inherits one ETFDH variant from each parent before the condition develops. When both parents carry one variant, each pregnancy has a 25% chance of an affected child, a 50% chance of a child who is a carrier, and a 25% chance of a child who inherits neither variant. People of any sex can inherit and pass on ETFDH variants because the ETFDH gene is on chromosome 4.
What does my ETFDH result mean for my family?
For ETFDH, family impact is usually discussed in a recessive pattern, which means parents are often healthy carriers. Brothers and sisters may also have the condition or be carriers, so relatives may want to learn whether the same gene change runs in the family. Children of someone with an ETFDH-related condition will usually be carriers unless the other parent also carries an ETFDH change.
Genetic information
Genetic testing
How you find out about variants
To learn how ETFDH genetic testing works, a lab uses a blood or saliva sample to read the ETFDH gene and look for variants. Results may identify one or two variants, or none, and can help clarify whether an inherited change is present.
When should I consider getting a genetic test?
If you or your child has repeated low blood sugar, muscle weakness, exercise trouble, or unexplained episodes during illness or fasting, testing the ETFDH gene may help confirm a fat-burning energy condition. It can also be considered if blood or urine tests suggest it, or if it runs in the family.
A genetic result is only one part of your health story
How much a genetic result can tell you varies based on the condition and the type of variant involved. Other factors, including lifestyle, environment, age, and medical history, also shape how the body functions over time. For some conditions, especially those influenced by many genes, genetic information offers context rather than certainty and is most useful when viewed alongside other parts of care. In other situations, a genetic result may give a clear answer. In areas like medication response, genetic results can also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how your body processes and responds to medicines. This helps explain why the same treatment may work well for one person, cause more side effects in another, or seem less effective in someone else. These differences are common and can influence how much of a drug reaches the body and how sensitive the body is to its effects.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in genes can affect the way a person responds to a medication. It looks at gene and drug patterns to help explain why the same treatment may work differently in different people. For many medicines, genes can influence how strongly a drug works or how the body handles it. This information can support treatment decisions that are better informed and more individualized. More detail on this topic is available in the LearnHub.
Drugs influenced by the ETFDH gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in predicting how medicines will work, so concerns about side effects, new symptoms, or medication changes are best discussed with your doctor.
History
Initially understood only through visible traits, later recognized as tied to a specific gene, ETFDH entered medical genetics through studies of people with a rare inherited energy metabolism condition now called multiple acyl-CoA dehydrogenase deficiency. In the late 20th century, researchers linked some affected families to changes in the ETFDH gene after earlier work had already identified related proteins in the same pathway. From these first observations, research expanded steadily. As DNA testing became more widely used, ETFDH helped clarify why some people with similar symptoms had different underlying genetic causes. This history also mattered in practice, because it improved diagnosis and supported recognition of forms that may respond to riboflavin treatment.